Matthew McEvoy

Dr. Matthew McEvoy

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Cancer Medicine
Verified
Journal Article
Open access
MMMatthew McEvoy
Matthew McEvoy
DSDavid A. Siegel
David A. Siegel
SDShifan Dai
Shifan Dai
MOMehmet Fatih Okcu
Mehmet Fatih Okcu
MZMark Zobeck
Mark Zobeck
Philip LupoPhilip Lupo
Philip Lupo
Background: While rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, past epidemiology studies of this malignancy used data that covered <30% of the US population. Therefore, we evaluated RMS incidence using data from U.S. Cancer Statistics (USCS) and survival trends using the National Program of Cancer Registries (NPCR), which covers 100% and 94% of the U.S. population, respectively.Methods: Incidence and survival were assessed for pediatric patients diagnosed with RMS during 2003–2017 and 2001–2016, respectively. Both demographic and clinical variables were evaluated. Age‐adjusted incidence rates, average annual percent change (AAPC), and 5‐year relative survival (RS) were calculated, all with corresponding 95% confidence intervals (CIs). Cox regression models were used to evaluate the impact of demographic and clinical variables on survival.Results: We identified 5656 primary RMS cases in USCS during 2003–2017. The age‐adjusted incidence rate was 4.58 per 1 million (95% CI: 4.46–4.70) with an AAPC of 0.3% (95% CI: −0.7 to 1.2%). In NPCR, 5‐year RS for all cases was 68.0% (95% CI: 66.6–69.3%). In multivariable analyses, non‐Hispanic (NH) Black cases had worse survival compared with NH White cases (hazard ratio [HR] = 1.16, 95% CI: 1.01–1.33).Conclusion: The incidence and survival rates were stable in the largest and most comprehensive population‐based analysis for pediatric RMS cases in the U.S. Additionally, we observed a survival disparity among NH Black cases. Findings from this study could inform interventions to address disparities, risk stratification strategies, and clinical trial design.

1 November 2017 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
MMMatthew McEvoy
Matthew McEvoy
NRNathan Robison
Nathan Robison
PMPeter Manley
Peter Manley
TYTorunn Yock
Torunn Yock
KKKristine Konopka
Kristine Konopka
AGAdam L. Green
Adam L. Green
The management of choroid plexus carcinoma (CPC) is challenging and multifaceted. Here, we discuss a 3-year-old girl with CPC and Li-Fraumeni syndrome who achieved full remission after surgery and chemotherapy, with radiation therapy spared. At recurrence, we used a novel, standard-dose cytotoxic chemotherapy regimen, focal proton radiation therapy, and targeted agents based on morphoproteomic analysis to achieve long-term survival. We highlight the rationale for our therapy at recurrence, as well as the risk-benefit analyses necessary in decision making for these patients. Our strategy may be effective in managing other patients with recurrent CPC and Li-Fraumeni syndrome.

29 December 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
MMMatthew McEvoy
Matthew McEvoy
ASAustin J. Stuckert
Austin J. Stuckert
MCMaria I. Castellanos
Maria I. Castellanos
MGMegan M. Gilbert
Megan M. Gilbert
TPThomas Pfeiffer
Thomas Pfeiffer
JPJacquelyn M. Powers
Jacquelyn M. Powers

14 September 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
MMMatthew McEvoy
Matthew McEvoy
MBMelissa M. Blessing
Melissa M. Blessing
KFKevin E. Fisher
Kevin E. Fisher
APArnold C. Paulino
Arnold C. Paulino
JNJed Nuchtern
Jed Nuchtern
MOM. Fatih Okcu
M. Fatih Okcu

15 March 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
MMMatthew McEvoy
Matthew McEvoy
ESElizabeth L. Seashore
Elizabeth L. Seashore
WCW. Susan Cheng
W. Susan Cheng
SCShondra Clay
Shondra Clay
JCJessica A. Casas
Jessica A. Casas
JFJennifer Foster
Jennifer Foster
Introduction: Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens. We analyze whether breaks (>30 days) between events and subsequent therapies affect survival and the associated decision‐making rationales. Methods: We reviewed data for patients with R/R extracranial solid tumors treated at Texas Children's Hospital between 2005 and 2023. Descriptive analysis was performed along with univariate chi‐square and independent sample t ‐tests. Cox regression analysis was used to evaluate postevent survival (PES). Results: Of the 466 patients (female: 47%; median age: 8.7 years), most common diagnoses were neuroblastoma (21.5%), rhabdomyosarcoma (19.1%), and osteosarcoma (16.1%). Patients had a median of 3 (interquartile range [IQR]: 1–4) R/R events with a median of 93 (IQR: 52–200) days between events. Of 438 patients who received ≥1 postevent therapy regimen, 116 (26.5%) experienced ≥1 break. Reasons for breaks varied evenly between intentional/goal‐concordant and undesired delays. Median PES for all patients was 12.9 (IQR: 5.8–31.4) months. In a multivariable Cox regression model, taking a >30‐day break in disease‐directed therapy was associated with prolonged PES (hazard ratio 0.58 [95% CI 0.45–0.76], p < 0.001). Conclusions: Most children with R/R solid tumors experience multiple events and therapy regimens without a break. Presence of a >30‐day break did not negatively affect survival, implying that time between therapy regimens can safely be offered to select patients to promote quality of life and thoughtful decision‐making, without compromising survival.

19 February 2025 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
MMMatthew McEvoy
Matthew McEvoy
SGStephanie Aprn Gruner
Stephanie Aprn Gruner
RMRossana Malatesta Muncher
Rossana Malatesta Muncher
ABAmanda Brown
Amanda Brown
JHJohn Md Hicks
John Md Hicks
NRNino Rainusso
Nino Rainusso
The standard therapy for Ewing sarcoma, the second most common bone tumor in children, includes alkylating agents such as ifosfamide and cyclophosphamide. One common adverse side effect of such agents is hemorrhagic cystitis, which typically presents with hematuria. We present the case of a patient with Ewing sarcoma who developed persistent gross hematuria followed by severe acute kidney injury while receiving chemotherapy. After interdisciplinary evaluation, including renal biopsy and assessment for lupus nephritis, a unique underlying diagnosis of immune-complex glomerulonephritis was determined. Herein, we discuss this novel case, including stepwise diagnostic evaluation, multimodal therapy, chemotherapy adjustments, and long-term disease monitoring.